Filtros de búsqueda

Lista de obras de Neill J Liptrott

Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation

artículo científico publicado en 2013

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

artículo científico publicado en 2012

Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach

artículo científico publicado en 2018

Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry

artículo científico publicado en 2008

Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches

artículo científico publicado en 2016

Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis

artículo científico publicado en 2020

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

artículo científico publicado en 2020

Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions

Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction

artículo científico publicado en 2011

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

artículo científico publicado en 2010

IFN-γ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV+ Patients

article

In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear Cells

artículo científico publicado en 2020

Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.

artículo científico publicado en 2013

Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter

artículo científico publicado en 2015

Nanomedicines for HIV therapy

artículo científico publicado en 2013

Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a ‘mixed matrix’

article by Neill J Liptrott et al published November 2014 in Nanomedicine

Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals ⬇️

artículo científico publicado el 15 de diciembre de 2011

Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients

artículo científico publicado en 2010

Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics

artículo científico publicado en 2020

Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir

artículo científico publicado en 2010

Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro

artículo científico publicado en 2013

The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC.

artículo científico publicado en 2009

The role of cytokines in the regulation of drug disposition: extended functional pleiotropism? ⬇️

artículo científico publicado el 8 de febrero de 2011

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda